Skip to main content
. Author manuscript; available in PMC: 2015 Jun 18.
Published in final edited form as: Mol Cancer Ther. 2014 Sep 19;13(11):2595–2606. doi: 10.1158/1535-7163.MCT-14-0422

Table 1. Summary of competitive binding results of new conjugates.

Cys-CO-Glu PSMA-1 PSMA-1–IR800 PSMA-1–Cy5.5
IC50, nmol/L 9.93 ± 0.07 2.30 ± 0.06 1.53 ± 0.14 2.07 ± 0.13

NOTE: IC50 is the concentration required to inhibit the binding of N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-S-[3H]-methyl-l-cysteine by 50%. Values are mean ± SD of 3 replicates.